心脉医疗(688016) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 332,189,385.86, a decrease of 7.23% compared to CNY 358,081,405.15 in the same period last year[4] - Net profit attributable to shareholders was CNY 129,636,898.33, down 29.66% from CNY 184,296,095.55 year-on-year[4] - Basic and diluted earnings per share decreased by 30.00% to CNY 1.05 from CNY 1.50 in the previous year[4] - The company's retained earnings rose to ¥1,214,597,510.58 in Q1 2025, up from ¥1,084,960,612.25 in Q1 2024[17] - The company reported a total comprehensive income of ¥124,733,344.22 in Q1 2025, down from ¥182,831,010.57 in Q1 2024[20] Cash Flow - The net cash flow from operating activities decreased by 81.11%, amounting to CNY 40,027,784.30 compared to CNY 211,948,663.78 in the previous year[4] - Cash inflow from operating activities in Q1 2025 was ¥190,732,776.15, a decline of 52.9% from ¥405,086,857.23 in Q1 2024[20] - The net cash flow from operating activities was $40,027,784.30, a significant decrease from $211,948,663.78 in the previous period, reflecting a decline of approximately 81%[21] - The net increase in cash and cash equivalents was -$1,080,353,621.70, an improvement from -$1,493,736,045.88, indicating a reduction in cash outflow of approximately 27.7%[21] - The ending balance of cash and cash equivalents was $978,477,623.44, down from $1,459,364,476.35, representing a decrease of about 33%[21] Assets and Liabilities - The total assets increased by 4.04% to CNY 4,464,876,823.41 from CNY 4,291,597,451.31 at the end of the previous year[5] - The company's cash and cash equivalents decreased to RMB 1,085,676,371.90 from RMB 2,170,604,749.23, representing a decline of about 50%[14] - Accounts receivable increased significantly to RMB 355,333,176.48 from RMB 209,761,864.13, marking a rise of approximately 69.5%[14] - The total current liabilities rose to RMB 458,518,305.05 from RMB 339,038,781.50, indicating an increase of around 35.3%[16] - The total liabilities of the company reached RMB 580,321,010.96, up from RMB 469,125,424.12, which is an increase of about 23.7%[16] Research and Development - Research and development expenses totaled CNY 29,051,147.32, a reduction of 38.37% from CNY 47,137,794.16, representing 8.75% of operating revenue[5] - Research and development expenses decreased to ¥15,941,366.59 in Q1 2025, down 31.0% from ¥23,190,117.20 in Q1 2024[18] Market Strategy - The company plans to focus on accelerating market access and promotion of aortic and peripheral interventional products in Europe, Latin America, and Asia-Pacific in 2025[9] - Six products are expected to obtain regulatory approval in 2025, with several others anticipated to complete registration or clinical trials[9] Shareholder Actions - The company repurchased a total of 1,952,089 shares, accounting for 1.58% of the total share capital, with a total expenditure of RMB 191,549,546.27[12][13] - The highest repurchase price during the first phase was RMB 103.96 per share, while the second phase saw a peak of RMB 119.82 per share[13] Accounting Changes - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[22]